加载中
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
常规交易时段
US$4.41
+US$0.17 · +4.01%
盘中时间采用ET。市场数据可能有所延迟。
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
日内区间
当前US$4.41
52周区间
当前US$4.41
盘中时间采用ET。市场数据可能有所延迟。
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
日内区间
当前US$4.41
52周区间
当前US$4.41
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 769.5万 USD | 769万 USD | 787.6万 USD | 572.9万 USD | 126万 USD |
| 销货成本 | 149.1万 USD | — | 6154.2万 USD | 7312.3万 USD | 7565.5万 USD |
| 毛利 | 620.4万 USD | 769万 USD | −5366.6万 USD | −6739.4万 USD | −7439.5万 USD |
| 研究与开发 | 2853.3万 USD | 5746.9万 USD | 6154.2万 USD | 7312.3万 USD | 7565.5万 USD |
| 销售、一般及管理费用 | 1379.5万 USD | 1845.7万 USD | 2253万 USD | 2292.7万 USD | 1839.3万 USD |
| 营业费用 | 4083.7万 USD | 8073.8万 USD | 2253万 USD | 2292.7万 USD | 1839.3万 USD |
| 利息收入 | 249.6万 USD | 525.5万 USD | 699.9万 USD | 222.3万 USD | 28.1万 USD |
| 折旧和摊销 | 129.1万 USD | 178.1万 USD | 185.4万 USD | 166.6万 USD | 119.3万 USD |
| 营业利润 | −3463.3万 USD | −7304.8万 USD | −7619.6万 USD | −9032.1万 USD | −9278.8万 USD |
| 净利润 | −3337.6万 USD | −6311.8万 USD | −6919.7万 USD | −8809.8万 USD | −9859.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$4.00
下跌空间 9.30%年度分割调整后的每股现金分配。
US$0.32
2013年（完整年度）+33.3% 自从 2012
US$0.24
2,012
US$0.32
2,013
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2014年8月29日 | US$0.0045Quarterly | — | 2014年10月2日 |
股息 | 2014年6月10日 | US$0.0045Quarterly | — | 2014年7月9日 |
股息 | 2014年3月3日 | US$0.0045Quarterly | — | 2014年4月2日 |
股息 | 2013年12月30日 | US$0.0045Quarterly | — | 2014年1月15日 |
股息 | 2013年9月3日 | US$0.0045Quarterly | — | 2013年10月3日 |
股息 | 2013年6月3日 | US$0.0035Quarterly | — | 2013年7月5日 |
除息 2014年8月29日
US$0.0045
Quarterly
支付日 2014年10月2日
除息 2014年6月10日
US$0.0045
Quarterly
支付日 2014年7月9日
除息 2014年3月3日
US$0.0045
Quarterly
支付日 2014年4月2日
除息 2013年12月30日
US$0.0045
Quarterly
支付日 2014年1月15日
除息 2013年9月3日
US$0.0045
Quarterly
支付日 2013年10月3日
除息 2013年6月3日
US$0.0035
Quarterly
支付日 2013年7月5日
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
